• Publications
  • Influence
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
BACKGROUND Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety ofExpand
  • 1,040
  • 33
  • PDF
Genomic Classification of Cutaneous Melanoma
We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients. We establish aExpand
  • 1,327
  • 31
  • PDF
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays
Merkel cell polyomavirus (MCV) is a newly‐discovered human tumor virus found in ∼80% of Merkel cell carcinoma (MCC). The rate of MCV infection among persons without MCC is unknown. We developed a MCVExpand
  • 284
  • 29
  • PDF
Leptin in Immunology1
Leptin is an adipokine which conveys information on energy availability. In humans, leptin influences energy homeostasis and regulates neuroendocrine function primarily in states of energyExpand
  • 445
  • 17
  • PDF
Leptin and reproduction: a review.
OBJECTIVE To review recent advances in understanding the role of leptin in the physiology and pathophysiology of reproduction, with a focus on relevant clinical situations. DESIGN A MEDLINEExpand
  • 478
  • 13
Next generation of immunotherapy for melanoma.
PURPOSE Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents forExpand
  • 203
  • 11
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
PURPOSE To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of theExpand
  • 299
  • 10
Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity.
High-fat diet-induced obesity (DIO) in rodents is associated with hyperleptinemia and resistance to leptin, but the response to agents acting downstream of leptin receptors remains unknown. WeExpand
  • 198
  • 10
  • PDF
The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications
Insulin-like growth factors (IGFs) are important mediators of growth, development, and survival, are synthesized by almost any tissue in the body, and their action is modulated by a complex networkExpand
  • 331
  • 9
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogeneExpand
  • 104
  • 8
  • PDF